Is Akums Drugs and Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Akums Drugs and Pharmaceuticals CMP Rs 767 (18 Sep 2026). Market cap Rs 12,059 Cr. ROE 7.70%. P/E 41.19x versus Industry P/E 37.32x.

Updated: 18 Sept 2026 • 9:28 am

Posted by:

Is Akums Drugs and Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Akums Drugs and Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 7.70% return on equity and a P/E of 41.19x against an Industry P/E of 37.32x. Whether Akums Drugs and Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Akums Drugs and Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 767 as of 18 September 2026, within its 52-week range of Rs 409.30 to Rs 796.55. Akums Drugs and Pharmaceuticals Ltd is a contract development and manufacturing organisation (CDMO) producing pharmaceutical formulations for other companies.

Akums Drugs and Pharmaceuticals sits in the Healthcare sector, and its 7.70% ROE and 41.19x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Akums Drugs and Pharmaceuticals

Akums Drugs and Pharmaceuticals Ltd is a contract development and manufacturing organisation (CDMO) producing pharmaceutical formulations for other companies. It is one of India's largest contract development and manufacturing organisations (CDMOs) for pharmaceutical formulations, producing medicines on behalf of other companies rather than selling its own branded portfolio at scale. At a market capitalisation of Rs 12,059 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Akums Drugs and Pharmaceuticals the Best Stock in Its Sector?

Akums Drugs and Pharmaceuticals makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 7.70% ROE with a 41.19x P/E against the sector's 37.32x Industry P/E. Akums Drugs and Pharmaceuticals trades close to its 37.32x Industry P/E, with a 7.70% ROE that trails Alivus Life Sciences and Sai Life Sciences in this comparison, consistent with the typically thinner margins of contract manufacturing versus branded or specialty pharma.

Metric	Akums Drugs and Pharmaceuticals
CMP (NSE)	Rs 766.70
52-Week High / Low	Rs 796.55 / Rs 409.30
Market Cap	Rs 12,059 Cr
P/E (TTM) vs Industry P/E	41.19x vs 37.32x
P/B	3.64
ROE	7.70%
EPS (TTM)	Rs 18.60
Dividend Yield	0.38%
Debt to Equity	0.05

Compare Akums Drugs and Pharmaceuticals Against Other Healthcare Sector Stocks

How Akums Drugs and Pharmaceuticals Compares Against Its Healthcare Sector Peers

The table below sets Akums Drugs and Pharmaceuticals against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Akums Drugs and Pharmaceuticals	12,059	41.19	7.70%	0.05
Alivus Life Sciences	17,029	28.24	16.94%	0.02
Sai Life Sciences	32,723	90.47	14.05%	0.12
Aarti Pharmalabs	7,157	34.39	8.89%	0.38
Peer average (3 companies)	-	51.03	13.29%	0.17

Against this peer set, Akums Drugs and Pharmaceuticals's 7.70% ROE is below the 13.29% peer average, and its P/E of 41.19x runs below the peer average of 51.03x. Akums Drugs and Pharmaceuticals trades close to its 37.32x Industry P/E, with a 7.70% ROE that trails Alivus Life Sciences and Sai Life Sciences in this comparison, consistent with the typically thinner margins of contract manufacturing versus branded or specialty pharma.

What Makes Akums Drugs and Pharmaceuticals Worth Watching in Healthcare

Near debt free: A debt to equity ratio of 0.05 gives Akums flexibility to invest in manufacturing capacity.
Scale as a leading CDMO: Being one of India's largest pharmaceutical contract manufacturers gives Akums scale and customer relationships across the industry.
Close to Industry P/E: A 41.19x P/E versus a 37.32x Industry P/E shows the stock trading close to Healthcare sector norms.

Akums Drugs and Pharmaceuticals Valuation: Is It Justified?

Akums Drugs and Pharmaceuticals trades close to its 37.32x Industry P/E, with a 7.70% ROE that trails Alivus Life Sciences and Sai Life Sciences in this comparison, consistent with the typically thinner margins of contract manufacturing versus branded or specialty pharma. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Aditya Birla Lifestyle Brands the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Akums Drugs and Pharmaceuticals and other Healthcare sector stocks.

How to Track Akums Drugs and Pharmaceuticals Before You Invest

Before deciding whether Akums Drugs and Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Akums Drugs and Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Akums Drugs and Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 7.70% ROE and a P/E of 41.19x against a 37.32x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Akums Drugs and Pharmaceuticals the best stock in its sector?

Ans. Akums Drugs and Pharmaceuticals has a 7.70% ROE and trades at 41.19x P/E against a 37.32x Industry P/E, and compares below the peer average ROE of 13.29% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Akums Drugs and Pharmaceuticals?

Ans. Akums Drugs and Pharmaceuticals was trading at Rs 766.70 on the NSE as of 18 September 2026, within its 52-week range of Rs 409.30 to Rs 796.55.

What sector does Akums Drugs and Pharmaceuticals belong to?

Ans. Akums Drugs and Pharmaceuticals is classified under the Healthcare sector on Univest.

How does Akums Drugs and Pharmaceuticals compare to its sector peers on P/E?

Ans. Akums Drugs and Pharmaceuticals's P/E of 41.19x is below the 51.03x average of the 3 named peers compared in this article.

What is Akums Drugs and Pharmaceuticals's return on equity?

Ans. Akums Drugs and Pharmaceuticals reported a return on equity of 7.70%, which is below the 13.29% average of its named peers in this comparison.

Should I invest in Akums Drugs and Pharmaceuticals based on its sector position?

Ans. Akums Drugs and Pharmaceuticals's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.